Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Jamile Shammo, MD
Jamile Shammo, MD, is from
Northwestern University.
Articles by Jamile Shammo, MD
Panel Predicts the Future for MDS: Treatment, Sequencing, Research
Hana Safah, MD
MDS
|
February 8, 2024
The panel shares their outlook for the future of MDS research and treatment.
View More
Biomarker Analysis on Inflammatory Effect for Luspatercept Versus Epoetin Alfa in Patients with MDS
Hana Safah, MD
MDS
|
February 8, 2024
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
View More
Patient-Reported Outcomes, Quality of Life for Luspatercept Versus Epoetin Alfa in MDS
Hana Safah, MD
MDS
|
February 8, 2024
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
View More
Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept
Hana Safah, MD
MDS
|
February 8, 2024
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
View More
Impact of Molecular Characteristics and Response to Luspatercept in Patients with MDS
Hana Safah, MD
MDS
|
February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
View More
Implications of the Full Analysis of the COMMANDS Trial of Luspatercept for MDS
Hana Safah, MD
MDS
|
February 8, 2024
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
View More
How Did the MEDALIST Trial Set the Stage for Luspatercept?
Hana Safah, MD
MDS
|
February 8, 2024
The panel discusses the evolution of MDS therapy and how the MEDALIST trial set the stage for luspatercept.
View More
Myelodysplastic Syndromes: Overview, Diagnosis, Therapy, and More
Hana Safah, MD
MDS
|
February 8, 2024
Dr. Safah gave an overview of myelodysplastic syndromes.
View More